REMARKS

Applicants recently submitted a Supplemental Information Disclosure Statement listing Vester et al. (Chemically modified oligonucleotides with efficient RNase H response, *J. Bioorg. Med. Chem. Lett.* 18:2296-2300, 2008). Vester et al. created a number of short DNA molecules each including one modified nucleoside and tested their ability to elicit RNase-mediated cleavage of complementary RNA *in vitro*. Vester et al. reported that molecules that include an alpha-L-oxy-LNA at one of two different positions in the central region of the molecule were capable of eliciting RNase-mediated cleavage of complementary RNA, albeit at a lower level than an otherwise identical molecule having a deoxyribonucleotide in the place of the alpha-L-oxyLNA (Table 1). It should be noted that the molecules containing an alpha-L-LNA had higher affinity for the complementary RNA than did the otherwise identical molecule having a deoxyribonucleotide in the place of the alpha-L-LNA (Table 1).

The present application presented experiments showing that a molecule having alpha-L-oxy-LNA regions flanking a deoxyribonucleotide region interrupted by an alpha-L-oxy-LNA can elicit RNase-mediated cleavage of complementary RNA (see paragraphs [0198]-[0200] of the published application).

No fees are believed due, but if any fees are due apply the charges or any credits to deposit account 06-1050, referencing attorney docket: 22460-0003US1.

Respectfully submitted,

Date:30 October 2008

/Anita L. Meiklejohn/
Anita L. Meiklejohn, Ph.D.
Reg. No. 35,283

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (877) 769-7945